This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Elena Feinstein, MD, PhD
Chief Scientist, RNA Therapeutics at Dexcel Ltd.


Elena Feinstein, MD, PhD., is currently Chief Scientist, RNA Therapeutics at Dexcel Ltd. She previously served as CSO of Quark Pharmaceuticals Inc since 2006 where she led Quark’s technology platform development, drug discovery and non-clinical development. Dr. Feinstein joined Quark in 1998, and since held increasingly senior positions, including Director of Research and Development, Vice President of Research and Vice President of Technology Development. Prior to joining Quark, Dr. Feinstein conducted research at the Weizmann Institute of Science as Doctoral Fellow, Post-Doctoral Fellow, Scientist and Senior Staff Scientist in the fields of cancer, apoptosis and functional gene discovery. She has a 2-year practical clinical experience from Clinical Pediatric Hospital No.1 in Moscow, Russia. Dr. Feinstein obtained her M.D. degree from the 2nd Moscow Medical Institute (Moscow Medical University) and completed her Ph.D. studies (Bondi Prize for Excellence) in the Department of Chemical Immunology, the Weizmann Institute of Science, Rehovot, Israel. Dr. Feinstein has been a leading or senior author of numerous publications in peer-reviewed journals and is named as an inventor on numerous patents.

Agenda Sessions

  • Chairman’s Remarks: Oligonucleotides for CNS and Cardiometabolic Diseases